论文部分内容阅读
目的探究肝癌组织中Bcl-2的表达与肝癌临床病理特征、患者预后之间的关系;观察siRNA抑制Bcl-2表达后,SMMC-7721增殖能力的变化。方法通过反转录PCR、免疫组织化学SP法以及Western blot法检测68例肝癌组织中Bcl-2的表达;根据Bcl-2表达水平的高低进行分组,比较不同组中肝癌临床病理特征及患者预后;通过siRNA抑制Bcl-2在SMMC-7721细胞中的表达,应用MTT法检测细胞增殖能力的变化。结果相较于癌旁组织,Bcl-2肝癌中表达明显升高;Bcl-2在肝癌组织中表达水平与肝癌临床病理特征存在明显相关性,Bcl-2表达水平较高的患者预后较差;siRNA抑制SMMC-7721细胞中Bcl-2的表达后细胞增殖能力显著降低。结论 Bcl-2的表达在肝癌组织中异常增高,且与肝癌临床病例特征及患者预后存在相关性;抑制Bcl-2的表达可降低肝癌细胞的增殖能力。
Objective To investigate the relationship between the expression of Bcl-2 in hepatocellular carcinoma and the clinicopathological features and prognosis of hepatocellular carcinoma (HCC). To observe the effect of Bcl-2 siRNA on the proliferation of SMMC-7721 cells. Methods The expression of Bcl-2 in 68 HCC tissues was detected by RT-PCR, immunohistochemical SP method and Western blot. According to the clinicopathological features and prognosis of HCC ; Inhibition of Bcl-2 expression in SMMC-7721 cells by siRNA, MTT assay was used to detect changes in cell proliferation. The results showed that the expression of Bcl-2 was significantly higher in Bcl-2 than in paracancer tissues. The expression of Bcl-2 in hepatocellular carcinoma was significantly correlated with the clinicopathological features of HCC and the prognosis of patients with higher Bcl-2 expression was poor. siRNA inhibited the expression of Bcl-2 in SMMC-7721 cells significantly reduced cell proliferation. Conclusions The expression of Bcl-2 is abnormally increased in HCC tissues and is correlated with clinical features and prognosis of HCC patients. Inhibition of Bcl-2 expression may reduce the proliferation of HCC cells.